981棋牌app下载

Global Market Study on Ineffective Esophageal Motility Treatment: Increasing Prevalence of GERD and Obesity to Propel Market Growth


Ineffective Esophageal Motility Treatment  Market
  • Published On : Jun-2020 |
  • Pages : 302 Pages |
  • Format : Ineffective Esophageal Motility Treatment  Market Ineffective Esophageal Motility Treatment  Market Ineffective Esophageal Motility Treatment  Market Ineffective Esophageal Motility Treatment  Market

981棋牌app下载The recent past has observed soaring preference for device-based treatment, as minimally-invasive and non-invasive options flood the market. Surgical treatment of ineffective esophageal motility follows the minimally-invasive approach, involving fundoplication devices and reflux management systems. Advancements in technology have taken place, such as radiofrequency stimulation to lower esophageal sphincter (LES) muscles, and RF energy remodelling the tissue, recreating the barrier function. Such technologically advanced treatment solutions are anticipated to propel the demand for ineffective esophageal motility treatment devices.

On the contrary, drug-based treatment with PPIs and antacids is the first line of therapy adopted by physician for the treatment of GERD, heartburn, and burning chest pain. Higher adoption of drug-based treatment is anticipated to drive the growth of the ineffective esophageal motility treatment market. However, advantages in terms of precision in treatment is being emphasized as the key factor that will boost the demand for device-based ineffective esophageal motility treatment in the near future. For instance, in 2017, spending of the Canadian government for PPIs in public drug programs was close to US$ 198 Mn.

Sedentary Lifestyle & Obesity Driving GERD Patient Pool - Key Market Driver

Increasing prevalence of gastroesophageal reflux disease is one of the most important factors that is responsible for the growth of the ineffective esophageal motility treatment market. Gastroesophageal reflux disease (GERD) is the most prevalent gastrointestinal disease in the U.S., as the prevalence of obesity is very high in the country. Factors increasing the complications of GERD include advanced age, increased tobacco use, and abdominal obesity. According to the World Gastroenterology Organization (WGO), the prevalence of gastroesophageal reflux disease is increasing throughout the world. There are reported differences in the prevalence of gastroesophageal reflux disease, ranging from 2.5% to 6.6% in Asia to up to 13.8% to 25.8% in North America. Increasing prevalence of gastroesophageal reflux disease is correlated with the increasing prevalence of obesity in several countries, as well as poor diet and poor lifestyle factors. Higher rate of comorbidities resulting in GERD and heartburn are anticipated to propel the ineffective esophageal motility treatment market size through 2030.

Advancements in Ineffective Esophageal Motility Treatment to Fuel Market Growth

GERD is one of the most prevalent gastrointestinal disorders in the U.S. It can lead to substantial morbidity; however, in very rare cases, it results in mortality. Risk factors include old age, sedentary lifestyle, tobacco usage, and excessive abdominal fat. Males as well as females suffer from GERD; however, the prevalence of this disease is found to be higher in males. The prevalence of gastroesophageal disorders generally increases with age, particularly after the age of 40. A clear shift towards OTC and generic formulations from branded drugs has been observed in the past, on account of patent expiry of popular of blockbuster drugs in the gastric motility disorder treatment market. Ease of manufacturing, availability of low-cost raw materials, and lower price point are aiding the rapid market entry of generic PPI and antacid drugs in lower income countries. These ineffective esophageal motility treatment market trends are anticipated to aid market growth over the coming years.

For instance, a generic version of Prilosec (AstraZeneca plc.) was launched by Lupin Pharmaceuticals, Inc. (2015) and Glenmark Pharmaceuticals (2014).

Regional Analysis of Ineffective Esophageal Motility Treatment Market

Sales of drugs and device-based ineffective esophageal motility treatment are growing in developing regions. Increasing prevalence of dysphagia, GERD, achalasia, and burning chest pain across East Asia and South Asia, with higher volumes of comorbidities in the region, are propelling the demand for ineffective esophageal motility treatment devices. While cost assistances importantly account for the increasing popularity of ineffective esophageal motility treatment across emerging and developing markets, a consistent rise in the number of healthcare facilities involving use of low-cost medication and minimally-invasive surgical treatment options is anticipated to drive the sales of ineffective esophageal motility treatment in the near future.  However, the high cost of treatment devices and lower reimbursement rates may remain as a key restraining factor for the growth of the ineffective esophageal motility treatment market during the forecast period.

COVID-19 Impact on Ineffective Esophageal Motility Treatment Market

Lockdowns and restricted travel have affected almost all countries around the world, due to the COVID-10 outbreak. This has affected most sectors, and the ineffective esophageal motility treatment market is bearing the brunt too. For now, amidst the pandemic, it is understandable that healthcare priorities have changed at hospitals and healthcare centers. Reduced visits by patients needing ineffective esophageal motility treatment will restrict market growth in the near-term. Also, raw material procurement issues and drug shortages are adding to the current crisis situation.

Analysts’ Viewpoint

A detailed analysis of the ineffective esophageal motility treatment market has brought our analysts to a conclusion that, this industry is still in the stage of infancy, and has significant growth prospects subject to the minimalistic nature of treatment devices. Drug-based treatment has evolved, owing to advanced PPI and prokinetic agents. The large patient pool and affordable treatment options are is anticipated to offer a lucrative landscape for key market players. North America and Europe dominate the global ineffective esophageal motility treatment market, owning to wider adoption of ineffective esophageal motility treatment drugs and preference for new treatment devices in operative procedures.

Ineffective Esophageal Motility Treatment Market - Scope of the Report

The latest publication by Persistence Market Research (PMR) on the global ineffective esophageal motility treatment market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global ineffective esophageal motility treatment market. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, and opportunities in the ineffective esophageal motility treatment market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.

Important indicators for the successful growth of the ineffective esophageal motility treatment market are presented in this comprehensive report, including year-on-year (Y-o-Y) growth analysis of the market and compounded annual growth rate (CAGR), which are described in an exhaustive way in PMR's research. This research study can support readers to know the demand for ineffective esophageal motility treatment and quantitative development opportunities during the study period.

981棋牌app下载The research is beneficial for shareholders in the ineffective esophageal motility treatment market, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the ineffective esophageal motility treatment market. The insights and wisdom presented in PMR’s study can be leveraged by shareholders in the ineffective esophageal motility treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics as well as information linked to macro- as well as micro-economic variables affecting the business scenario in the Ineffective esophageal motility treatment market are also included in the current study. Depending on potential developments in the ineffective esophageal motility treatment market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this ineffective esophageal motility treatment market report, minor companies and new entrants can make suitable company choices to achieve traction in the ineffective esophageal motility treatment market.

Key Segments of Ineffective Esophageal Motility Treatment Market

PMR’s study on the ineffective esophageal motility treatment market offers information divided into four important segments — product, indication, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

  • Devices
    • Reflux Management Systems
    • Endoscopic Pain Modulators
    • Endostaplers
    • Radiofrequency (RF) Ablation Devices
    • Myotomy Devices
  • Drugs
    • H2 Receptor Antagonists
    • Antacids
    • Proton Pump Inhibitors
    • Dopamine Antagonists
    • Prokinetic Agents
    • Calcium Channel Blockers

Indication

  • Dysphagia
  • GERD
  • Burning Chest Pain
  • Achalasia

End User

  • Institutional Sales
    • Hospitals
    • Ambulatory Surgical Centers
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Mail Order Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Key Questions Answered in PMR’s Ineffective Esophageal Motility Treatment Market Report

  • Which regions will continue to remain the most profitable regional markets for ineffective esophageal motility treatment market players?
  • Which factors will induce a change in the demand for ineffective esophageal motility treatment during the assessment period?
  • How will changing trends impact the ineffective esophageal motility treatment market?
  • How can market players capture the low-hanging opportunities in the ineffective esophageal motility treatment in developed regions?
  • What are the winning strategies of stakeholders in the ineffective esophageal motility treatment market to upscale their position in this landscape?
  • What are the restraints that investors need to be aware of and might tackle while investing in the ineffective esophageal motility treatment market?
  • What are the developmental trends in ineffective esophageal motility treatment sectors that will impact the market?
  • How can businesses in the ineffective esophageal motility treatment market avail the growth opportunities in developed and emerging sectors?

Ineffective Esophageal Motility Treatment Market: Research Methodology

981棋牌app下载In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the ineffective esophageal motility treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of the conclusions.

981棋牌app下载Secondary resources referred to by analysts during the production of the ineffective esophageal motility treatment market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

981棋牌app下载Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the ineffective esophageal motility treatment market, and makes PMR’s projections on the growth prospects of the ineffective esophageal motility treatment market more accurate and reliable.

Companies covered in Ineffective Esophageal Motility Treatment Market Report

  • Johnson & Johnson 
  • Mylan Pharmaceutical 
  • MediGus Ltd. 
  • Torax Medical
  • Medtronic plc.
  • AstraZeneca plc.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc.
  • Bayer AG
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • LABORIE
  • Mederi Therapeutics, Inc.
  • Becton, Dickinson and Company (C. R. Bard, Inc.)
  • EndoGastric Solutions, Inc
  • Olympus
  • Pentax

981棋牌app下载Ineffective Esophageal Motility Treatment Market

Back To Top 850土豪版官方网站 850土豪版手机下载 850土豪版手游棋牌 850土豪版游戏官方下载 850土豪版赠送欢乐豆